UBS Downgrades Merck (MRK) to Neutral
More News related to MRK
- Notable Midday ETF Movers 11/20: XLV, EWJ Higher; XHB, XLE, SMH Lower
- Merck Receives CHMP Positive Opinion for New Fertility Treatment, ELONVA(R)
- Notable 52-Week NYSE New Highs and Lows 11/19: CAH, DCI, RX, KG, MRK, TSL Highs; SNV, WNR Low
- Merck's Investigational Anacetrapib Phase IIb Study Results Presented at American Heart Association Annual Scientific Sessions
- Merck (MRK) Announces Results of COZAAR Study; Increased Dose Reduced Death or Hospitalization from Heart Failure
UBS downgrades Merck (NYSE: MRK) from Buy to Neutral and cuts its price target from $43 to $40.
Merck & Co., Inc. provides various products for human and animal health in the United States and internationally.
Related Categories
DowngradesStocks Mentioned
+1.13Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
